Larimar Therapeutics, Inc. LRMR
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia ("FA"). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| R&D | $154.2M | $73.3M | $27.7M | $24.2M | $38.4M | $31.4M | $20.8M | $47.9M | $40.8M | $39.9M |
| SG&A | $18.3M | $17.6M | $14.1M | $12.3M | $12.1M | $11.4M | $2.4M | $13.2M | $12.2M | $18.3M |
| Total operating expenses | $172.5M | $90.9M | $41.8M | $36.5M | $50.5M | $42.8M | $23.2M | $61.1M | $53.0M | $58.2M |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M | -$42.8M | -$23.2M | -$61.1M | -$53.0M | -$58.2M |
| Interest expense | — | — | — | — | — | — | $1.8M | $1.9M | $165.0K | $529.0K |
| Pre-tax income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M | -$42.5M | -$23.2M | -$61.4M | -$52.0M | -$57.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M | -$42.5M | -$23.1M | -$61.4M | -$52.0M | -$57.9M |
| EPS, basic | — | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | — | — | — | — |
| EPS, diluted | — | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | -3.80 | -1.90 | -1.90 | -2.12 |
| Shares, diluted (wtd. avg.) | — | $61.3M | $43.9M | $25.8M | $17.2M | $11.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M | $68.1M | $1.0M | $49.3M | $40.8M | $32.4M |
| Short-term investments | $51.4M | $150.2M | $60.0M | $91.6M | — | $24.5M | $43.0M | $68.7M | $61.3M | $96.8M |
| Total current assets | $142.0M | $195.3M | $90.2M | $120.7M | $72.2M | $98.0M | $4.8M | $121.3M | $104.9M | $130.9M |
| Property, plant and equipment | $622.0K | $881.0K | $684.0K | $831.0K | $1.0M | $1.0M | $274.0K | $375.0K | $528.0K | $661.0K |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M | $104.7M | $5.2M | $121.8M | $105.5M | $131.6M |
| Accounts payable | $5.2M | $2.4M | $1.3M | $1.7M | $1.7M | $2.6M | $3.5M | $3.6M | $3.0M | $2.6M |
| Total current liabilities | $64.8M | $24.4M | $9.5M | $10.7M | $8.8M | $9.0M | $5.9M | $13.3M | $7.3M | $9.9M |
| Long-term debt | — | — | — | — | — | — | $14.5M | $20.0M | $20.0M | $3.2M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M | $15.0M | $5.9M | $28.5M | $27.3M | $9.9M |
| Retained earnings | -$434.8M | -$269.2M | -$188.6M | -$151.6M | -$116.2M | -$65.6M | -$23.1M | -$350.9M | -$289.6M | -$237.5M |
| Total equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M | $89.7M | -$694.0K | $2.9M | $78.2M | $121.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M | -$42.2M | -$22.7M | -$51.5M | -$43.8M | -$52.0M |
| Depreciation and amortisation | $350.0K | $318.0K | $311.0K | $318.0K | $326.0K | $155.0K | $78.0K | $261.0K | $188.0K | $212.0K |
| Stock-based compensation | $7.0M | $8.8M | $7.6M | $6.6M | $5.5M | $2.2M | $129.0K | $9.6M | $8.3M | $10.1M |
| Capital expenditure | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K | $62.0K | $83.0K | $108.0K | $55.0K | $660.0K |
| Investing cash flow | $100.3M | -$85.4M | $33.4M | -$91.0M | $24.2M | $17.1M | -$83.0K | -$6.9M | $35.6M | $51.4M |
| Financing cash flow | $65.1M | $161.9M | $30.0K | $75.3M | $19.9M | $93.6M | $19.4M | $66.9M | $16.6M | -$2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-163942.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |